Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$15.96 - $23.15 $202,692 - $294,005
12,700 New
12,700 $231,000
Q2 2022

Aug 15, 2022

SELL
$17.23 - $37.73 $136,117 - $298,067
-7,900 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$28.92 - $41.83 $228,468 - $330,457
7,900 New
7,900 $249,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $950M
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Worth Venture Partners, LLC Portfolio

Follow Worth Venture Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Worth Venture Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Worth Venture Partners, LLC with notifications on news.